- Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD more...
Chromoblastomycosis is a chronic fungal infection of the skin and the subcutaneous tissue caused by traumatic inoculation of a specific group of dematiaceous fungi (usually Fonsecaea pedrosoi, Phialophora verrucosa, Cladosporium carrionii, or Fonsecaea compacta) through the skin.
Several cases of infection by Exophiala species have appeared in the literature. Chromoblastomycosis is classified among the subcutaneous mycoses and is ubiquitous; however, the prevalence is higher in rural populations in countries with a tropical or subtropical climate, such as Madagascar in Africa and Brazil in South America.
Since its identification in the early 1910s, the name of the disease has been frequently misused to encompass other infections caused by dematiaceous fungi. More recently, the advent of immunosuppressive therapies and diseases brought more confusion because of the identification of new agents and clinical settings. With the introduction of the concept of phaeohyphomycosis by McGinnis in 1983, differentiation among these diseases became more obvious. The features of chromoblastomycosis are distinctive enough to consider chromoblastomycosis an independent clinical entity. The infection should not be confused with mycoses, such as mycetoma or phaeohyphomycosis, caused by other dematiaceous fungi.
Nowadays, the term chromoblastomycosis is restricted to the cases in which sclerotic cells are present in tissue. Sclerotic cells, also known as Medlar bodies, are globe-shaped, cigar-colored, thick-walled structures that are 4-12 µm in diameter (see the image below).
Medlar first described them in 1915. These structures multiply by septation, and they induce a purulent and granulomatous inflammatory reaction in tissue (see Histologic Findings).
Contrary to what appears in some textbooks, chromoblastomycosis was first described by Max Rudolph in 1914 and not by Lane or Medlar in 1915. In 1987, Castro and Castro reported that Max Rudolph, a German physician living in Brazil, published a preliminary communication where the first 6 cases of the disease were described. Rudolph was also able to isolate a dark-colored fungus from 4 of 6 patients; this fungus grew in culture as a dark grey-to-black–colored furlike colony. Rudolph believed this fungus to be a type of blastomycete, and he successfully inoculated the disease in 4 white rats and 2 monkeys. Surprisingly, he did not describe the histologic aspects of the disease or the pathognomonic sclerotic cells, which both Lane and Medlar described 1 year later.
In 1928, Hoffman mentioned that in Cuba in 1908 Guiteras had observed 10 cases of a disease known as chapa in which the clinical aspects resembled those of chromoblastomycosis. Unfortunately, those cases were not published. In 1920, 2 Brazilian physicians, Pedroso and Gomes, published 4 cases that had been under observation for many years, the first one since 1911. According to them, all 4 cases were caused by P verrucosa. Two years later, in 1922, Brumpt concluded that the agents isolated by Pedroso and Gomes could not be classified as Phialophora species, and he coined the denomination Hormodendrum pedrosoi, later renamed F pedrosoi by Negroni in 1936. By 1930, new cases had been described outside the American continent in France, Sumatra, and Poland.
Four different genera are now widely accepted to cause chromoblastomycosis: F pedrosoi, P verrucosa, C carrionii, and F compacta. Rare cases of chromoblastomycosis caused by Rhinocladiella aquaspersa and Exophiala species have also been reported, allowing the inclusion of these species among those that cause the disease.[15, 16, 17, 18, 19]
The infection usually results from a traumatic cutaneous injury that is often not remembered or realized by the patient. The agents often gain entry into the human body by contact with wood splinters or thorns.
The fungi most commonly reported as causing chromoblastomycosis are F pedrosoi, C carrionii, and P verrucosa. A small number of cases due to F compacta, R aquaspersa, and different species of Exophiala have also been reported. In 2007, Chaetomium funicola was identified as a cause of chromoblastomycosis in Panama.
Several authors have demonstrated that a number of different dematiaceous fungi can be isolated from nature. In 1937, Conant demonstrated that a fungus called Cadophora americana, which was isolated from timber, was actually the same organism as P verrucosa. Later isolations were obtained in several countries from materials, such as plants, palm trees, grass, and soil. C carrionii has been isolated from cactaceae, both from the thorns and from the medullae, in Venezuela. C carrionii is the most common agent of chromoblastomycosis in that country, and trauma due to plants is believed to inoculate the skin with the fungus. The fungal cells in human tissue present with the same features as those observed in the inner portions of the plants.
The lesions develop slowly at the site of implantation, producing a warty nodule, which tends to be limited to the skin and the subcutaneous tissue. Over the years, the nodule grows centripetally. In many instances, the central parts of the lesion heal, leaving ivory-colored scars. The disease tends to spread to neighboring healthy skin, forming plaques, which, at times, can involve a whole limb. When nodular lesions predominate over the plaques, the disease assumes a typical cauliflower aspect. Both lymphatic dissemination and cutaneous dissemination have been described.
A new species of Fonsecaea, Fonsecaea nubica, morphologically similar to F pedrosoi and F monophora, has been described in association with chromoblastomycosis. Rhinocladiella aquaspersa may also be a causative agent.
The disease has been described worldwide, but the incidence is greater in tropical and subtropical regions located between 30° N and 30° S.
An estimated 20% of cases are found in temperate climates, such as in Japan, Canada, Finland,[28, 29] and Romania and the Czech Republic. Chromoblastomycosis most commonly affects male agricultural workers in rural regions of North America, Central America, and South America, but chromoblastomycosis does occur worldwide, including Europe, England, India, South Africa, and Australia. The highest incidence of chromoblastomycosis in the world is in the African country of Madagascar, and a large number of cases have been reported in Japan. A survey in the Brazilian Amazon disclosed an extremely high incidence of chromoblastomycosis (1.6 cases per 10,000 population) in a village called Monte Negro, in the state of Rondonia.
Countries with the highest number of cases are Madagascar and Brazil. Several different African and Latin American countries, such as Gabon, Colombia, Venezuela, Cuba, the Dominican Republic, and Mexico, also have high prevalence rates.
F pedrosoi infection is most commonly observed in humid climates, whereas C carrionii infection is normally found in dry areas.
Farming is the most common occupation in patients with chromoblastomycosis.
Fonsecaea monophora is the predominant etiologic agent of chromoblastomycosis in southern China.
Chromoblastomycosis in central Kerala, India, was found to be more common among male agriculturists than others. The most common etiologic species isolated was F pedrosoi.
No racial predilection is usually noted. In one Brazilian study in São Paulo State, chromoblastomycosis was evident most in white male rural workers, who averaged age 60 years.
Most series reports indicate a clear male predominance, although a small number of reports describe similar male-to-female ratios. Approximately 70% of cases are seen in men. The explanation for this male predominance is not clear, but men are assumed to be more commonly involved in agricultural work and are more prone to inflict injuries on themselves, thereby causing self-inoculation, rather than women who are supposedly more dedicated to house jobs.
The possible inhibitory effect of female hormones on the growth of fungi may partially explain the relatively low number of cases in females.
Patients with the disease are most commonly aged 30-50 years. The period between inoculation and disease development is believed to last years, explaining the scarcity of children with chromoblastomycosis. The disease is rarely found in children exposed to the same environmental conditions as adults.
The prognosis for chromoblastomycosis tends to be good, especially for small and localized lesions. When the affected area is large, as in severe cases, cure is difficult, although control is easily achieved. Cicatricial and unaesthetic scars are the rule after the disease is eliminated.
Success in a specialized Brazilian center with clinical care, laboratory support, and pharmaceutical care was noted in 18 cases, with a cure rate of 80%.
Mortality due to chromoblastomycosis is a rare event.
Morbidity relates directly to the severity of the disease. Initially, in the papule or nodule phase, the disease is asymptomatic. When the nodules coalesce, forming large plaques and sometimes involving the whole limb, complications may appear. Common complications include ulceration, lymphedema, and secondary infection.
Fungal causes of chromoblastomycosis are becoming more frequent opportunistic pathogens in solid organ transplant recipients, producing significant morbidity.
Rubin HA, Bruce S, Rosen T, McBride ME. Evidence for percutaneous inoculation as the mode of transmission for chromoblastomycosis. J Am Acad Dermatol. 1991 Nov. 25(5 Pt 2):951-4. [Medline].
Castro LG, Pimentel ER, Lacaz CS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years' experience. Int J Dermatol. 2003 May. 42(5):408-12. [Medline].
McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 1983 Jan. 8(1):1-16. [Medline].
Medlar EM. A cutaneous infection caused by a new fungus Phialophora verrucosa with a study of the fungus. J Med Res. 1915. 32:507-22.
Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol. 1992. 30(1):1-10. [Medline].
Terra F, Torres M, Fonseca Filho O. Novo tipo de dermatite verrucosa; micose por Acrotheca com associado de leishmaniose. Brasil Medico. 1922. 36:363-8.
Lane CG. A cutaneous disease caused by a new fungus Phialophora verrucosa. J Cutan Dis. 1915. 33:840-6.
Castro RM, Castro LG. On the priority of description of chromomycosis. Mykosen. 1987 Sep. 30(9):397-403. [Medline].
Hoffman WH. Die Chromoblastomykose in Kuba. Arch Schiffs u Tropen Hyg. 1928. 32:485-7.
Pedroso A, Gomes JM. 4 casos de dermatite verrucosa produzida pela Phialophora verrucosa. Ann Paulistas de Medicina e Cirurgia. 1920. 11:53-61.
Brumpt E. Prés de Parasitologie. 3rd ed. Paris, France: Masson; 1922. 1105.
Negroni R. Estudio del primer caso argentino de cromomicosis, Fonsecaea (Negroni) pedrosoi (Brumpt) 1921. Rev Inst Bacteriol. 1936. 7:419-26.
Rippon JW. Chromoblastomycosis and related dermal infections caused by dematiaceous fungi. Medical Mycology. The Pathogenic Fungi and the Pathogenic Actinomycetes. 2nd ed. Philadelphia, Pa: WB Saunders; 1982. 249-76.
Lacaz CS, Porto E, Martins JEC. Fungos, actinomicetos e algas de interesse medico. Micologia Medica. 8th ed. Sao Paulo, Brazil: Sarvier; 1991. 373-86.
South DA, Brass C, Stevens DA. Chromohyphomycosis. Treatment wit ketoconazole. Arch Dermatol. 1981 May. 117(5):311-2. [Medline].
Naka W, Harada T, Nishikawa T, Fukushiro R. A case of chromoblastomycosis: with special reference to the mycology of the isolated Exophiala jeanselmei. Mykosen. 1986 Oct. 29(10):445-52. [Medline].
Barba-Gomez JF, Mayorga J, McGinnis MR, Gonzalez-Mendoza A. Chromoblastomycosis caused by Exophiala spinifera. J Am Acad Dermatol. 1992 Feb. 26(2 Pt 2):367-70. [Medline].
Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992 Nov. 31(11):805-12. [Medline].
Padhye AA, Hampton AA, Hampton MT, Hutton NW, Prevost-Smith E, Davis MS. Chromoblastomycosis caused by Exophiala spinifera. Clin Infect Dis. 1996 Feb. 22(2):331-5. [Medline].
Piepenbring M, Caceres Mendez OA, Espino Espinoza AA, Kirschner R, Schofer H. Chromoblastomycosis caused by Chaetomium funicola: a case report from Western Panama. Br J Dermatol. 2007 Nov. 157(5):1025-9. [Medline].
Conant NF. The occurrence of a human pathogenic fungus as a saprophyte in nature. Mycologia. 1937. 29:597-8.
Zeppenfeldt G, Richard-Yegres N, Yegres F. Cladosporium carrionii: hongo dimorfico en cactaceas de la zona endemica para la cromomicosis en Venezuela. Rev Iberoam Micol. 1994. 11:61-3.
Najafzadeh MJ, Sun J, Vicente V, Xi L, van den Ende AH, de Hoog GS. Fonsecaea nubica sp. nov, a new agent of human chromoblastomycosis revealed using molecular data. Med Mycol. 2010 Mar 22. [Medline].
Badali H, Bonifaz A, Barrón-Tapia T, Vázquez-González D, Estrada-Aguilar L, Cavalcante Oliveira NM, et al. Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Med Mycol. 2010 Jan 29. [Medline].
Brygoo ER, Destombes P. Epidemiologie de la chromoblastomycose humaine. Bull Inst Pasteur. 1975. 74:219-43.
Nishimoto K. Chromomycosis in Japan. Ann Soc Belg Med Trop. 1981 Sep. 61(3):405-12. [Medline].
Berger L, Langeron M. Sur un type noveau de chromomycose observé au Canada (Torula bergeri n. sp). Ann Parasit Hum Comp. 1949. 24:574-99.
Putkonen T. [Chromomycosis in Finland. The possible role of the Finnish sauna in its spreading]. Hautarzt. 1966 Nov. 17(11):507-9. [Medline].
Sonck CE. Chromomycosis in Finland. Dermatology. 1975. 19:189-93.
Pradhan SV, Talwar OP, Ghosh A, Swami RM, Shiva Raj KC, Gupta S. Chromoblastomycosis in Nepal: a study of 13 cases. Indian J Dermatol Venereol Leprol. 2007 May-Jun. 73(3):176-8. [Medline].
Xi L, Sun J, Lu C, et al. Molecular diversity of Fonsecaea (Chaetothyriales) causing chromoblastomycosis in southern China. Med Mycol. 2009 Feb. 47(1):27-33. [Medline].
Chandran V, Sadanandan SM, Sobhanakumari K. Chromoblastomycosis in kerala, India. Indian J Dermatol Venereol Leprol. 2012 Nov-Dec. 78(6):728-33. [Medline].
Marques GF, Masuda PY, Sousa JM, Barreto JA, Wachholz PA. Clinical and demographic profile of chromoblastomycosis in a referral service in the midwest of São Paulo state (Brazil). An Bras Dermatol. 2015 Jan-Feb. 90(1):140-2. [Medline]. [Full Text].
Schieffelin JS, Garcia-Diaz JB, Loss GE Jr, Beckman EN, Keller RA, Staffeld-Coit C, et al. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis. 2014 Mar 17. [Medline].
Salgado CG, da Silva MB, Yamano SS, Salgado UI, Diniz JA, da Silva JP. Cutaneous localized annular chromoblastomycosis. J Cutan Pathol. 2009 Feb. 36(2):257-61. [Medline].
El Euch D, Mokni M, Haouet S, Trojjet S, Zitouna M, Ben Osman A. [Erythemato-squamous papular and atrophic plaque on abdomen: chromoblastomycosis due to Fonsecaea pedrosoi]. Med Trop (Mars). 2010 Feb. 70(1):81-3. [Medline].
Sharma NL, Sharma VC, Mahajan V, Shanker V, Sarin S. Chromoblastomycosis with underlying osteolytic lesion. Mycoses. 2007 Nov. 50(6):517-9. [Medline].
Krishna S, Shenoy MM, Pinto M, Saxena V. Two cases of axillary chromoblastomycosis. Indian J Dermatol Venereol Leprol. 2016 Jan 21. [Medline].
França K, Villa RT, de Azevedo Bastos VR, Almeida AC, Massucatti K, Fukumaru D, et al. Auricular Chromoblastomycosis: A Case Report and Review of Published Literature. Mycopathologia. 2011 Feb 17. [Medline].
Sharma A, Hazarika NK, Gupta D. Chromoblastomycosis in Sub-Tropical Regions of India. Mycopathologia. 2010 Jan 22. [Medline].
Naveen KN, Naik AS, Shetty PC, Pai VV, Hanumanthayya K, Udupishastry D. Chromoblastomycosis presenting as a phagedenic ulcer on the face. Int J Dermatol. 2011 Sep 19. [Medline].
Silva CM, da Rocha RM, Moreno JS, et al. [The coconut babaçu (Orbignya phalerata martins) as a probable risk of human infection by the agent of chromoblastomycosis in the State of Maranhão, Brazil]. Rev Soc Bras Med Trop. 1995 Jan-Mar. 28(1):49-52. [Medline].
Salgado CG, da Silva JP, Diniz JA, et al. Isolation of Fonsecaea pedrosoi from thorns of Mimosa pudica, a probable natural source of chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2004 Jan-Feb. 46(1):33-6. [Medline].
Martinez EC, Rey Valeiron C, Yegres F, Reyes R. [The goat: approach to an animal model in human chromomycosis]. Invest Clin. 2005 Jun. 46(2):131-8. [Medline].
Tsuneto LT, Arce-Gomez B, Petzl-Erler ML, Queiroz-Telles F. HLA-A29 and genetic susceptibility to chromoblastomycosis. J Med Vet Mycol. 1989. 27(3):181-5. [Medline].
Verma S, Verma GK, Singh G, Kanga A, Sharma V, Gautam N. Facial chromoblastomycosis in sub-Himalayan region misdiagnosed as cutaneous leishmaniasis: brief report and review of Indian literature. Dermatol Online J. 2012 Oct 15. 18(10):3. [Medline].
Azevedo CM, Marques SG, Santos DW, Silva RR, Silva NF, Santos DA, et al. Squamous Cell Carcinoma Derived From Chronic Chromoblastomycosis in Brazil. Clin Infect Dis. 2015 Feb 13. [Medline].
Campolina SS, Caligiorne RB, Rezende-Silva S, Hahn RC, De Hoog GS. A skin infection mimicking chromoblastomycosis by a Capnodialean fungus. Med Mycol. 2009 Feb. 47(1):81-5. [Medline].
Bui AQ, Espana EM, Margo CE. Chromoblastomycosis of the conjunctiva mimicking melanoma of the ciliary body. Arch Ophthalmol. 2012 Dec 1. 130(12):1615-7. [Medline].
Anjaneyan G, Jagadeesan S, Thomas J. Cytodiagnostic copper pennies in chromoblastomycosis. Indian Dermatol Online J. 2016 Mar-Apr. 7 (2):145-6. [Medline].
Miranda MF, Silva AJ. Vinyl adhesive tape also effective for direct microscopy diagnosis of chromomycosis, lobomycosis, and paracoccidioidomycosis. Diagn Microbiol Infect Dis. 2005 May. 52(1):39-43. [Medline].
Saxena AK, Jain S, Ramesh V, Singh A, Capoor MR. Chromoblastomycosis: Demonstration of abundant microorganisms on microscopy of a scaly crust following intralesional corticosteroids. J Eur Acad Dermatol Venereol. 2014 Feb 14. [Medline].
Vidal MS. Estudo imunoquimco de um antigeno de Fonsecaea pedrosoi e padronizao de teiicas sorologicas para cromoblastomicose causada por este fungo. Sao Paulo, Brazil: University of Sao Paulo; 2002.
Oberto-Perdigon L, Romero H, Perez-Blanco M, Apitz-Castro R. [An ELISA test for the study of the therapeutic evolution of chromoblastomycosis by Cladophialophora carrionii in the endemic area of Falcon State, Venezuela]. Rev Iberoam Micol. 2005 Mar. 22(1):39-43. [Medline].
de Andrade TS, Cury AE, de Castro LG, Hirata MH, Hirata RD. Rapid identification of Fonsecaea by duplex polymerase chain reaction in isolates from patients with chromoblastomycosis. Diagn Microbiol Infect Dis. 2007 Mar. 57(3):267-72. [Medline].
Najafzadeh MJ, Sun J, Vicente VA, de Hoog GS. Rapid identification of fungal pathogens by rolling circle amplification using Fonsecaea as a model. Mycoses. 2011 Sep. 54(5):e577-82. [Medline].
Ogawa MM. Cromoblastomicose: Teraplicas e alternativos linfocintilograpicas. Sao Paulo, Brazil: Tese de Mestrado, Escola Paulista de Medicina; 2001.
Salfelder K, de Liscano TR, Sauerteig E. Atlas of Fungal Pathology. Kluwer/Dordrecht; 1990. 145-50.
Jawitz RS, Calder KB, Turner LM, Schlauder S, Morgan MB. Cryptic "chromo-fibroma". Am J Dermatopathol. 2007 Dec. 29(6):573-5. [Medline].
Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009 Feb. 47(1):3-15. [Medline].
Antonello VS, Silva MC, Cambruzzi E, Kliemann DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop Sao Paulo. 2010 Dec. 52(6):329-31. [Medline].
Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988. 544:504-16. [Medline].
Graybill JR. Future directions of antifungal chemotherapy. Clin Infect Dis. 1992 Mar. 14 Suppl 1:S170-81. [Medline].
Pradinaud R, Bolzinger T. Treatment of chromoblastomycosis. J Am Acad Dermatol. 1991 Nov. 25(5 Pt 1):869-70. [Medline].
Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 1996 Jun. 134 Suppl 46:33-6; discussion 40. [Medline].
Keating GM. Posaconazole. Drugs. 2005. 65(11):1553-67; discussion 1568-9. [Medline].
Kinbara T, Fukushiro R, Eryu Y. Chromomycosis--report of two cases successfully treated with local heat therapy. Mykosen. 1982 Dec. 25(12):689-94. [Medline].
Bassas-Vila J, Fuente MJ, Guinovart R, Ferrándiz C. Chromoblastomycosis: response to combination therapy with cryotherapy and terbinafine. Actas Dermosifiliogr. 2014 Mar. 105(2):196-8. [Medline].
Pimentel ER, Castro LG, Cuce LC, Sampaio SA. Treatment of chromomycosis by cryosurgery with liquid nitrogen: a report on eleven cases. J Dermatol Surg Oncol. 1989 Jan. 15(1):72-7. [Medline].
Ameen M. Managing chromoblastomycosis. Trop Doct. 2010 Apr. 40(2):65-7. [Medline].
Badali H, Fernández-González M, Mousavi B, Illnait-Zaragozi MT, González-Rodríguez JC, de Hoog GS, et al. Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba. Mycopathologia. 2013 Mar 8. [Medline].
Lyon JP, Pedroso e Silva Azevedo Cde M, Moreira LM, de Lima CJ, de Resende MA. Photodynamic antifungal therapy against chromoblastomycosis. Mycopathologia. 2011 Oct. 172(4):293-7. [Medline].
Yang Y, Hu Y, Zhang J, Li X, Lu C, Liang Y, et al. A refractory case of chromoblastomycosis due to Fonsecaea monophora with improvement by photodynamic therapy. Med Mycol. 2012 Feb 7. [Medline].
Hu Y, Huang X, Lu S, Hamblin MR, Mylonakis E, Zhang J, et al. Photodynamic Therapy Combined with Terbinafine Against Chromoblastomycosis and the Effect of PDT on Fonsecaea monophora In Vitro. Mycopathologia. 2015 Feb. 179(1-2):103-9. [Medline]. [Full Text].
Slesak G, Inthalad S, Strobel M, Marschal M, Hall M Jr, Newton PN. Chromoblastomycosis after a leech bite complicated by myiasis: a case report. BMC Infect Dis. 2011 Jan 12. 11:14. [Medline]. [Full Text].
Rojas OC, González GM, Moreno-Treviño M, Salas-Alanis J. Chromoblastomycosis by Cladophialophora carrionii Associated with Squamous Cell Carcinoma and Review of Published Reports. Mycopathologia. 2015 Feb. 179(1-2):153-7. [Medline].
Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001. 44(1-2):1-7. [Medline].
Zhang J, Xi L, Lu C, et al. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China. Mycoses. 2009 Mar. 52(2):176-81. [Medline].
Tagami H, Ginoza M, Imaizumi S, Urano-Suehisa S. Successful treatment of chromoblastomycosis with topical heat therapy. J Am Acad Dermatol. 1984 Apr. 10(4):615-9. [Medline].
da Glória Teixeira de Sousa M, Júnior WB, Spina R, Lota PR, Valente NS, Brown GD, et al. Topical application of Imiquimod as a treatment for Chromoblastomycosis. Clin Infect Dis. 2014 Mar 14. [Medline].